NCT03309943

Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The central objective of this project is to obtain proof-of-concept data demonstrating the effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to personal smoking environments and behavioral responses in a laboratory smoking behavior task. Human cigarette smokers (N = 50) will take photographs of locations where they do and do not smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg) or placebo prior to completing: A) An MRI session assessing neural responses to personal smoking/non-smoking environments, standard smoking/non-smoking environments and proximal smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response to environmental cues.

Conditions

• Cigarette Smoking

Interventions

Type	Name	Description
DRUG	Propranolol	Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
DRUG	Placebo	Participants will take one dose of Placebo on two separate occasions.

Timeline

• Start date: 2018-01-16
• Primary completion: 2019-07-15
• Completion: 2019-07-15
• First posted: 2017-10-16
• Last updated: 2020-08-13
• Results posted: 2020-08-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study